Literature DB >> 19143028

Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense.

S M Goodyear1, M D Amatangelo, M E Stearns.   

Abstract

BACKGROUND: The CD133(hi) sub-population of prostate epithelial cells has been demonstrated to possess tumor-initiating capacity consistent with that of the cancer stem cell theory. However, the involvement of oncogenes such as c-myc has not been fully elucidated in the CD133(hi) sub-population.
METHODS: We have isolated primary prostate cell strains (IBC-10a) and immortalized them by transfection with hTERT. The in vitro and in vivo tumorigenic capacity of isolated CD133(hi) and CD133(lo) cells was evaluated with respect to c-myc expression using specific sense and anti-sense oligonucleotides.
RESULTS: Freshly immortalized cells consisted of <3.3% CD133(hi)/CD24(hi) sub-population (SP). "Prostaspheres" generated from single CD133(hi) cells in the presence of EGF consisted of approximately 10% CD133(hi) SPs in 12-21 day cultures. A single Prostasphere generated from single CD133(hi) cells (6-10 cell stage at day 6 injected i.t.) produced dysplastic lesions in NOD-SCID mice (n = 4/5). Treatment of Prostaspheres from CD133(hi) SPs in vitro with c-myc or cyclin D1 anti-sense oligonucleotides totally blocked colony forming ability and growth. Furthermore, treatment of fully formed, 6-day Prostaspheres for 48 hr with c-myc anti-sense significantly reduced c-myc expression and their ability to generate lesions in NOD-SCIDs (n = 10 Prostaspheres injected i.t./mouse).
CONCLUSIONS: These data demonstrate for the first time that a single CD133(hi) cell is competent to generate Prostaspheres in vitro and that CD133(hi) Prostaspheres require c-myc to grow and form dysplastic lesions in vivo. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19143028      PMCID: PMC2720608          DOI: 10.1002/pros.20918

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  36 in total

1.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.

Authors:  T Jiborn; A Bjartell; P A Abrahamsson
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

2.  Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer.

Authors:  H Bonkhoff
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

Review 3.  Basic science aspects of prostate cancer.

Authors:  T J Dorkin; D E Neal
Journal:  Semin Cancer Biol       Date:  1997-02       Impact factor: 15.707

4.  Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas.

Authors:  H Bonkhoff; U Stein; G Aumüller; K Remberger
Journal:  Prostate       Date:  1996-10       Impact factor: 4.104

5.  c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny.

Authors:  I Arnold; F M Watt
Journal:  Curr Biol       Date:  2001-04-17       Impact factor: 10.834

6.  Deregulated expression of c-Myc depletes epidermal stem cells.

Authors:  R L Waikel; Y Kawachi; P A Waikel; X J Wang; D R Roop
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

Review 7.  Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.

Authors:  H Bonkhoff
Journal:  Prostate Suppl       Date:  1998

8.  Telomerase activity: a prevalent marker of malignant human prostate tissue.

Authors:  H J Sommerfeld; A K Meeker; M A Piatyszek; G S Bova; J W Shay; D S Coffey
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

Review 9.  Neuroendocrine differentiation and hormone-refractory prostate cancer.

Authors:  P A Abrahamsson
Journal:  Prostate Suppl       Date:  1996

10.  Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression.

Authors:  A T Collins; F K Habib; N J Maitland; D E Neal
Journal:  J Cell Sci       Date:  2001-11       Impact factor: 5.285

View more
  9 in total

1.  Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice.

Authors:  Mark E Stearns; Michael D Amatangelo; Devika Varma; Chris Sell; Shaun M Goodyear
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

2.  Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells.

Authors:  Haiyen E Zhau; Hui He; Christopher Y Wang; Majd Zayzafoon; Colm Morrissey; Robert L Vessella; Fray F Marshall; Leland W K Chung; Ruoxiang Wang
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

3.  MYC and Prostate Cancer.

Authors:  Cheryl M Koh; Charles J Bieberich; Chi V Dang; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Genes Cancer       Date:  2010-06

Review 4.  Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-03-17

5.  Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits.

Authors:  Avani R Vyas; Michelle B Moura; Eun-Ryeong Hahm; Krishna Beer Singh; Shivendra V Singh
Journal:  J Cell Biochem       Date:  2016-05-26       Impact factor: 4.429

6.  c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer.

Authors:  Michael D Amatangelo; Shaun Goodyear; Devika Varma; Mark E Stearns
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

7.  Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells.

Authors:  Jianjun Zhou; Honghe Wang; Virginetta Cannon; Karen Marie Wolcott; Hongbin Song; Clayton Yates
Journal:  Mol Cancer       Date:  2011-09-14       Impact factor: 27.401

8.  RPS2: a novel therapeutic target in prostate cancer.

Authors:  Min Wang; Youji Hu; Mark E Stearns
Journal:  J Exp Clin Cancer Res       Date:  2009-01-12

9.  Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

Authors:  Anastasia Wyce; Yan Degenhardt; Yuchen Bai; BaoChau Le; Susan Korenchuk; Ming-Chih Crouthame; Charles F McHugh; Robert Vessella; Caretha L Creasy; Peter J Tummino; Olena Barbash
Journal:  Oncotarget       Date:  2013-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.